Global Anti-Aging Drug Development Accelerates with Multiple Breakthroughs in 2026

　　【Pharmaceutical Network Industry DynamicsSince 2026, the global anti-aging drug research field has welcomed several new breakthroughs, including multiple new drug applications for clinical trials, the launch of large-scale clinical validations, and the approval of advanced medical devices.
 

Recently, the FDA approved the Investigational New Drug (IND) application for ER-100 from Life Biosciences. Reportedly, the core concept of Life Biosciences is to reset age-related epigenetic abnormalities and restore function through partial epigenetic reprogramming while maintaining cellular identity. ER-100, built on a partial epigenetic reprogramming platform, uses AAV as a gene delivery vector to inject OSK factor-encoding sequences into the vitreous cavity, restoring youthful cell phenotypes while reducing potential tumorigenic risks.
 

According to data disclosed by Life Biosciences at the 12th Annual Meeting on Aging Research and Drug Discovery, ER-100 has completed intravitreal injection studies in various ophthalmology-related animal models, with consistent neuroprotective and functional improvement signals observed.
 

On March 2, Nanjing Ruichu Pharmaceuticals announced that its self-developed innovative drug RC017, which targets aging mechanisms for the treatment of eye diseases, has officially received approval from the U.S. FDA for new drug clinical trials.
 

Public information shows that Ruichu Pharmaceuticals, established in June 2021, is a company in China that focuses on targeting the biology of aging and developing innovative drugs for the prevention and reversal of aging-related diseases. RC017 is one of the company's core pipelines that focuses on "targeting mechanisms of aging," adopting a unique "three major R&D platforms" strategy and making arrangements around key biological pathways such as chronic inflammation, senescent cell clearance, and cellular reprogramming.
 

On January 16, the injectable poly-L-lactic acid filler independently developed by Yizhen Bio officially received approval from the National Medical Products Administration (NMPA) for market launch. According to reports, this product is an injectable filler for temporal indications. Its "Cloud Microsphere" utilizes domestically developed MEDBIOMA(®) poly-L-lactic acid and is manufactured using the EvolaONE(®) patented technology. The material has been clinically used in tens of thousands of safe craniofacial implant cases and has passed both NMPA and FDA certifications.
 

In January, ConnexBio revealed that its "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Different Doses of Injectable Coenzyme I (NAD+) for the Treatment of Ovarian Function Decline" (2025LP03594) has officially been approved by the National Medical Products Administration (NMPA). Injectable Coenzyme I (NAD+) represents a significant exploration in the field of reproductive health and anti-aging, aiming to explore new pathways to improve the success rate of assisted reproduction for refractory infertility.
 

From a holistic perspective, driven by policy guidance, technological accumulation, clinical needs, and capital support, China's domestically produced anti-aging sector is accelerating towards breakthroughs. In the future, domestically produced anti-aging drugs will gradually evolve from "followers" to become strong competitors in the global anti-aging field, promoting the upgrading of China's pharmaceuticals and health industry while also contributing more solutions to address the global challenge of population aging.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.